The move to the In Vitro Diagnostic Regulation (IVDR) has changed the day-to-day reality for many IVD manufacturers. What used to be a primarily self-driven conformity approach under the IVDD has shifted toward deeper evidence expectations, stronger oversight, and more formal post-market responsibilities.
For teams trying to keep products on the market, launch new assays, or expand a portfolio across the EU, ivdr compliance is no longer a one-time project. It is an operating model. The good news is that most of the work is manageable when you break it into clear building blocks: classification, technical documentation, clinical evidence, quality systems, and post-market surveillance.
This article walks through the biggest changes, what regulators and Notified Bodies expect to see, and practical ways to reduce avoidable delays.
Understanding the IVDR Landscape and What Has Changed
The Shift From IVDD to IVDR
IVDR (Regulation (EU) 2017/746) was designed to strengthen patient safety and improve confidence in diagnostic performance across the EU. Compared with the IVDD, it brings more structure and more scrutiny.
The most noticeable differences for manufacturers are:
- A risk-based classification system that drives the depth of assessment
- A much larger role for Notified Bodies for most devices
- Greater emphasis on clinical evidence and performance evaluation
- Stronger requirements for post-market surveillance and ongoing performance monitoring
- Higher expectations for transparency, traceability, and documentation quality
Under the IVDD, many devices could be placed on the market through self-declaration. Under IVDR, far more devices require Notified Body involvement, and the evidence bar is higher even for products with long market history.
For manufacturers, the practical impact is timing and capacity. You need more planning, more cross-functional coordination, and earlier engagement with external stakeholders.
The New Risk-Based Classification System
IVDR introduced four classes for IVDs: A, B, C, and D. The class is not just a label. It dictates the conformity assessment route, the depth of review, and what kind of Notified Body engagement is needed.
In broad terms:
- Class A tends to be lower risk and may allow a simpler conformity path in many cases.
- Class B introduces moderate risk and typically requires more structured evidence and review.
- Class C includes higher-risk devices where performance evidence and oversight requirements increase meaningfully.
- Class D includes the highest-risk categories, often linked to critical clinical decisions or public health impact, and typically requires the most rigorous assessment and oversight.
Classification work should not be treated as a quick regulatory step. It is a foundational decision that drives your timelines, costs, and documentation plan. A misclassification can trigger rework, delays, and in some cases, a complete reassessment of your submission package.
Why Notified Bodies Matter More Than Ever
Under IVDR, Notified Bodies are central for most devices beyond the lowest-risk categories. They evaluate conformity assessment submissions, review technical documentation, assess performance evaluation evidence, and examine your post-market surveillance approach.
Notified Bodies also have defined scopes under IVDR, meaning you need to select one that is designated for your device type and intended use. That sounds simple, but in practice it involves:
- Confirming the Notified Body’s designation and capacity
- Aligning early on the evidence expectations and submission structure
- Planning realistic review timelines, including rounds of questions
- Preparing for audits and sampling of technical documentation
A common mistake is treating Notified Body engagement as a late-stage step. IVDR has made capacity planning a real constraint in the market. Early relationship-building and early dossier readiness reduce the risk of being stuck in a queue with an incomplete package.
Getting Classification Right Without Guesswork
Mapping Intended Use to the Right Class
IVDR classification depends heavily on intended use, target population, and the impact of results on clinical decisions. A device that supports screening, diagnosis, prognosis, or therapy selection may fall into higher-risk classes because of how its output affects patient management.
A practical way to approach classification is to document, in plain language first:
- Who uses the device and in what setting
- What clinical question the result answers
- What happens if the result is wrong or delayed
- Whether results affect high-stakes decisions
- Whether the device supports blood safety or public health functions
From there, align your intended use statement, IFU claims, and performance endpoints so they consistently support the classification rationale. Misalignment between marketing claims and technical documentation is a frequent trigger for regulatory questions.
Common Classification Pitfalls
Manufacturers often run into trouble when:
- Intended use is written too broadly, pushing the device into a higher risk class
- Intended use is too vague, making it hard to justify classification decisions
- Legacy products are assumed to fit old pathways without a fresh IVDR assessment
- Companion diagnostics, infectious disease tests, or screening tools are treated like routine assays
A strong classification file should read like a clear argument. It should show that you understand the classification rules, and that the product claims and evidence plan match the risk level.
Technical Documentation Under IVDR
What a Strong Technical File Needs to Include
IVDR technical documentation is not just a collection of documents. It is a coherent story about the device, how it works, why it is safe, and how you know it performs as intended.
While the exact content varies by device class and type, most compliant files include:
- Device description, variants, and configuration control
- Intended purpose and clear clinical claims
- Design and manufacturing information, including key suppliers
- Risk management documentation aligned with the device lifecycle
- Performance evaluation documentation, including scientific validity, analytical performance, and clinical performance
- Labeling and instructions for use, aligned with claims and limitations
- Stability, transport, and environmental performance evidence when relevant
- Post-market surveillance plan and performance follow-up approach
- Traceability, including UDI where applicable and linkages to clinical evidence
The goal is clarity. Reviewers should be able to follow the chain from intended use to evidence, then to labeling, then to post-market monitoring without having to guess what your product is truly claiming.
Making the Performance Evidence Easy to Review
Performance evaluation is a centerpiece of IVDR. Manufacturers are expected to demonstrate:
- Scientific validity: that the analyte or marker is meaningfully linked to a clinical condition or physiological state.
- Analytical performance: that the device measures what it claims with appropriate accuracy, precision, sensitivity, specificity, and robustness.
- Clinical performance: that the results are clinically meaningful for the intended use and population.
A common pain point is presenting evidence in a way that is technically correct but difficult to review. Strong files are structured, cross-referenced, and consistent. They use clear definitions, explain study design choices, and make limitations visible instead of burying them.
Writing a Clinical Evaluation Plan That Actually Works
A clinical evaluation plan under IVDR should do more than list activities. It should function as a roadmap that connects your claims to how you will prove them and maintain them over time.
An effective plan typically includes:
- The clinical background and rationale for claims
- The target population and intended setting
- Clear performance endpoints tied to intended use
- Evidence sources, including literature, existing studies, and new investigations where needed
- A gap analysis explaining what is missing and how you will address it
- A plan for integrating post-market data into ongoing evaluation
If gaps exist, acknowledge them early. Trying to force-fit weak evidence into a strong claim often leads to Notified Body pushback and longer review cycles.
Post-Market Surveillance Under IVDR
PMS Is Now a Core Compliance Activity
Under IVDR, post-market surveillance is not just complaint handling. It is an active system designed to monitor real-world performance and safety, detect trends, and feed that learning back into risk management and performance evaluation.
Your PMS system should be capable of:
- Collecting and analyzing user feedback and performance information
- Tracking complaints, incidents, and potential signals
- Monitoring field performance across relevant populations and settings
- Supporting corrective and preventive actions when needed
- Maintaining traceability and consistency between PMS findings and technical documentation updates
Manufacturers that build PMS into normal operations tend to have smoother audits and fewer surprises. PMS should not be a yearly scramble to assemble reports.
Performance Follow-Up and the “Living” Evidence Model
IVDR pushes manufacturers toward continuous evidence. Even if your pre-market package is strong, performance does not stop being assessed after CE marking. Instead, your evidence base becomes a living set of inputs that evolves as you gather real-world data.
This has two big implications:
- You need systems that can capture quality data consistently.
- You need processes that can translate that data into updates for clinical evaluation, risk management, labeling, and training when appropriate.
A mature PMS and performance follow-up program can become an advantage. It helps you defend your product’s value, respond quickly to issues, and build trust with users.
Practical Strategies to Streamline IVDR Compliance
Integrating IVDR Requirements Into Your QMS
For many companies, the fastest path to sustainable ivdr compliance is to stop treating it as a parallel regulatory project and instead embed it in the quality system.
Key integration points include:
- Document control that supports tight traceability and version alignment
- Risk management processes that reflect ongoing post-market inputs
- Design control processes that clearly connect requirements, verification, validation, and performance evidence
- Supplier controls that address critical components and external manufacturing steps
- Change management that triggers regulatory impact assessment and evidence updates
When the QMS is aligned, the technical file becomes easier to maintain, and audits become more predictable.
Building a Culture That Supports Compliance
IVDR success depends on people, not just documents. Even a well-written dossier can unravel if teams do not follow controlled processes or do not understand why certain evidence matters.
Practical ways to strengthen culture include:
- Clear ownership of key deliverables across regulatory, clinical, quality, R&D, and manufacturing
- Training that focuses on real workflows, not just slide decks
- Regular cross-functional reviews of claims, evidence, labeling, and PMS findings
- Encouraging early escalation when evidence gaps or field issues appear
Leadership support matters here. When compliance is treated as part of product quality and patient safety, teams make better decisions under pressure.
Using Technology to Reduce Documentation Friction
Most IVDR programs generate heavy documentation. Digital tools can reduce the risk of errors and improve speed, especially when multiple teams contribute.
Manufacturers often benefit from:
- Document management systems that enforce version control and approval workflows
- Systems that link requirements, risks, verification, and validation evidence
- Tools that support literature review traceability and study evidence tracking
- Dashboards for PMS signals, complaint trends, and CAPA status
The goal is not technology for its own sake. It is removing manual bottlenecks that slow reviews and create inconsistency.
Challenges and Common Pitfalls to Watch For
Underestimating the Workload and Timelines
A recurring issue is assuming that legacy documentation can be lightly adjusted for IVDR. In many cases, the structure, evidence depth, and traceability expectations are different enough that significant rework is required.
Plan for:
- More time to build performance evaluation packages
- More time for Notified Body review and questions
- More internal time for cross-functional alignment and document control
- More effort to operationalize PMS and performance follow-up
A realistic plan is often the difference between a controlled transition and a last-minute scramble.
Notified Body Engagement That Starts Too Late
Even strong manufacturers can lose time if they engage a Notified Body late or approach them without a cohesive dossier strategy.
To reduce risk:
- Confirm scope alignment early
- Discuss expected evidence types and dossier format upfront
- Schedule milestones that include time for questions and corrective updates
- Treat Notified Body feedback as a structured input, not a negotiation
A steady, professional relationship tends to produce better outcomes than a rushed, transactional approach.
Misalignment Between Claims, Evidence, and Labeling
Another common issue is inconsistency. If your marketing materials, intended use, IFU, and performance evidence do not line up, reviewers will ask questions.
Before submission, do a claim-to-evidence audit:
- List each key claim
- Identify exactly which studies and data support it
- Confirm that the IFU reflects limitations and appropriate use
- Ensure your risk file accounts for the claim’s clinical impact
This simple exercise can prevent long review loops.
Looking Forward: Trends That Will Shape IVDR
Advanced Diagnostics and Personalized Medicine
As diagnostics become more targeted, especially in oncology and infectious disease management, regulators will likely continue to emphasize evidence quality and clinical relevance. Devices that guide therapy selection or identify high-risk patient groups may face deeper scrutiny because of downstream clinical impact.
Software, AI, and Data Integrity Expectations
Digital components are increasing in diagnostics, from algorithmic interpretation to connected reporting systems. As these features grow, expectations around software lifecycle controls, cybersecurity, and data integrity will become more central to compliance conversations.
Manufacturers should be prepared to show that software-related risks and performance are managed systematically, and that updates are controlled with clear regulatory impact assessment.
Global Alignment Pressures
Many manufacturers operate across regions. IVDR may also influence how global documentation is structured, with more emphasis on traceable evidence, consistent claims, and robust post-market monitoring. Even when requirements differ by region, building one strong evidence foundation can reduce duplication.
Closing Thoughts: Making IVDR Compliance Sustainable
IVDR has raised expectations, but it has also clarified what “good” looks like: clear classification rationale, strong performance evidence, well-structured technical documentation, and a real post-market system that learns over time.
Manufacturers who succeed tend to do three things well. They plan early, they integrate compliance into everyday quality systems, and they treat evidence as a continuous lifecycle activity rather than a submission milestone.
With that approach, ivdr compliance becomes less about firefighting and more about building products that are easier to defend, easier to maintain, and more trusted in the market.
